CSA
RCKT icon

Cornerstone Select Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Cornerstone Select Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-22,265
Closed -$149K – 113
2025
Q1 		$149K Buy
22,265
+3,220
+17% +$31.8K 0.14% 109
2024
Q4 		$239K Buy
+19,045
New +$287K 0.23% 95

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Cornerstone Select Advisors's RCKT Position: Q2 2025 in Review

Cornerstone Select Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 22,265 shares — an estimated $149K sold.

Cornerstone Select Advisors first reported a position in RCKT in Q4 2024 and held it in 2 quarters. The position peaked at $239K in Q4 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Cornerstone Select Advisors reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cornerstone Select Advisors sold 22,265 Rocket Pharmaceuticals shares in Q2 2025, an estimated $149K.
  • Cornerstone Select Advisors first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Cornerstone Select Advisors's Rocket Pharmaceuticals position peaked at $239K in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Cornerstone Select Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.